BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21415221)

  • 21. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
    Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
    Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.
    van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V
    Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645
    [No Abstract]   [Full Text] [Related]  

  • 24. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
    Annibali O; Petrucci MT; Martini V; Tirindelli MC; Levi A; Fossati C; Del Bianco P; Mandelli F; Foa R; Avvisati G
    Cancer; 2005 Feb; 103(3):582-7. PubMed ID: 15611977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and efficacy of bortezomib in relapsed multiple myeloma.
    Jagannath S
    Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
    [No Abstract]   [Full Text] [Related]  

  • 29. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
    Leblebjian H; Noonan K; Paba-Prada C; Treon SP; Castillo JJ; Ghobrial IM
    Am J Hematol; 2015 Jun; 90(6):E122-3. PubMed ID: 25703132
    [No Abstract]   [Full Text] [Related]  

  • 31. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
    Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
    Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia.
    Gnemmi V; Leleu X; Provot F; Moulonguet F; Buob D
    Am J Kidney Dis; 2012 Sep; 60(3):487-91. PubMed ID: 22721930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
    Leleu X; Moreau AS; Weller E; Roccaro AM; Coiteux V; Manning R; Nelson M; Leduc R; Robu D; Dupire S; Hatjiharissi E; Burwick N; Darre S; Hennache B; Treon SP; Facon T; Gertz MA; Ghobrial IM
    Leuk Lymphoma; 2008 Jun; 49(6):1104-7. PubMed ID: 18452095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
    He Q; Zhao X; He Y; Tan D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [PAD regimen for relapsed or refractory patients with multiple myeloma].
    Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 40. [Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
    Li J; Zeng LJ; Zhao Y; Su C; Huang BH
    Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):543-7. PubMed ID: 19954643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.